Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04969731
Other study ID # ILC-P3-PAN
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date September 7, 2021
Est. completion date June 2027

Study information

Verified date November 2021
Source GC Cell Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

PURPOSE: This phase III clinical trial evaluates the efficacy and safety of adjuvant Immuncell-LC therapy combined with gemcitabine versus adjuvant gemcitabine single therapy after R0 or R1 resection in patients with pancreatic ductal adenocarcinoma.


Description:

Open-label, Randomized, Multi-center, Parallel, Phase III Clinical Trial


Recruitment information / eligibility

Status Recruiting
Enrollment 408
Est. completion date June 2027
Est. primary completion date December 2026
Accepts healthy volunteers No
Gender All
Age group 19 Years to 80 Years
Eligibility Inclusion Criteria: 1. Age >/=20 years old, </=80 years old. 2. Histologically or cytologically confirmed pancreatic ductal adenocarcinoma that fulfill the following requirements: - Participants have undergone a radical full resection (R0) or boundary resection (R1) operation and has elapsed at least two weeks after the resection based on the baseline, up to 12 weeks. - Noncancerous ascites. - No evidence of distant metastasis (such as liver, peritoneum) - No evidence of distant metastasis in other distant abdominal or extra-abdominal organs - Scheduled to be given gemcitabine alone as postoperative adjuvant chemotherapy 3. Eastern Cooperative Oncology Group-performance status (ECOG-PS) 0 - 2 4. Life expectancy is at least 12 weeks. 5. Adequate organ and marrow function at the screening and baseline as defined below: - Absolute neutrophil count = 1,500/µL - Hemoglobin level = 9 g/dL - Platelet count = 100,000/µL - BUN, serum creatinine = 1.5 × institutional upper limit of normal (ULN) - AST, ALT = 2.5 × institutional upper limit of normal (ULN) - PT (INR), activated partial thromboplastin time (aPTT) = 1.5 × institutional upper limit of normal (ULN) 6. Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: 1. Received anticancer therapy including chemotherapy, biological therapy, immunotherapy, hormone therapy, radiation therapy, and other anti-cancer treatments. Note: Neo-adjuvant therapy for pancreatic cancer is allowed. 2. Measurable lesions identified in the pancreas after surgery. 3. Known history at the screening as defined below. - Confirmed cases of acquired immunodeficiency, which can be exacerbated by immunotherapy. - History of autoimmune diseases that can be exacerbated by immunotherapy. (e.g. rheumatoid arthritis, systemic lupus, vascular inflammation, multiple sclerosis, adolescent-induced insulin-dependent diabetes, T-cell lymphoma, etc.) - Active hepatitis B or hepatitis C virus infection confirmed. - Human immunodeficiency virus (HIV) antibody test results are positive during screening - History of malignant tumors other than pancreatic cancer within five years of screening. Note: skin basal cell cancer/squamous cell cancer, local prostate cancer, thyroid papillary cancer or cervical epithelial cancer can be participated even if 5 years have passed since successful treatment. 4. Known associated disease at the screening as defined below. - Severe nephropathy: estimated glomerular filtration rate (eGFR)‡ <30 mL/min/1.73 m2 - Chest X-ray shows epileptic pneumonia or pulmonary fibrosis with clear, clinical symptoms. - Severe infections or other uncontrolled active infectious diseases requiring the administration of antibiotics, antibacterial drugs, antifungal drugs, antiviral drugs, etc. that may affect safety and validity evaluation during clinical trials, as determined by the tester. - Holder of thromboembolic disease or bleeding diatheses - Those who are deemed unfit to participate in clinical trials because they are not controlled or require treatment (e.g., heart disease, pulmonary dysfunction, renal dysfunction, low blood pressure, hypertension, bone marrow inhibition, liver metastasis, hepatitis, history of alcoholism, myocardial infarction, etc.) 5. Received Immuncell-LC, Natural Killer (NK) cell therapy or other cell therapy drugs within three years prior to screening. 6. Anaphylaxis to the main ingredient or sub-brothers of Immuncell-LC or Gemcitabine 7. Patients who cannot collect blood for manufacturing Immuncell-LC depending on the investigator's judgment. 8. Pregnant or lactating women 9. Fertility women and men who are not willing to use appropriate contraception from screening to 24 weeks after final administration of Immuncell-LC and/or Gemgitabine 10. Received or applied with another investigational products or investigational device within 4 weeks prior to signing a written informed consent document. 11. Patients who are inappropriate or impossible to participate in the trial due to non-recovery of resection or prior chemotherapy depending on the investigator's judgment.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Immuncell-LC
IV
Gemcitabine
IV

Locations

Country Name City State
Korea, Republic of Seoul National University Hospital Seoul Daehak-ro, Jongno-gu

Sponsors (1)

Lead Sponsor Collaborator
GC Cell Corporation

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recurrence free survival (RFS) by independent review Recurrence free survival is defined as the time from randomization to the date of the recurrence confirmed by independent reviewer Up to approximately 36 months after Last Patient In
Secondary Overall survival (OS) Overall survival is defined as the time from randomization to death due to any cause. Up to approximately 36 months after Last Patient In
Secondary Recurrence free survival (RFS) by investigator Recurrence free survival is defined as the time from randomization to the date of the recurrence confirmed by investigator Up to approximately 36 months after Last Patient In
Secondary Carbohydrate antigen 19-9 level Carbohydrate antigen 19-9 level Up to approximately 36 months after Last Patient In
Secondary Quality of Life (QoL) EORTC QLQ-C30 The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A higher score represents a higher ("better") level of functioning, or a higher ("worse") level of symptoms. Up to approximately 36 months after Last Patient In
Secondary Quality of Life (QoL) EORTC QLQ-PAN26 The module comprises 26 questions assessing pain, dietary changes, jaundice, altered bowel habit, emotional problems related to pancreatic cancer, and other symptoms (cachexia, indigestion, flatulence, dry mouth, taste changes). The answers range is the following: not at all - 1 point, a little - 2 points, quite a bit - 3 points, very much - 4 points. Minimum score is 26, maximum is 106. The higher total score represents the worse quality of life. Up to approximately 36 months after Last Patient In
See also
  Status Clinical Trial Phase
Recruiting NCT05209074 - Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma Phase 1
Recruiting NCT04927780 - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Phase 3
Recruiting NCT05048524 - Peri-operative SLOG for Localized Pancreatic Cancer Phase 2
Terminated NCT04042480 - A Study of SGN-CD228A in Advanced Solid Tumors Phase 1
Completed NCT03257150 - A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer N/A
Terminated NCT04400903 - Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer
Active, not recruiting NCT05462717 - Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors Phase 1
Active, not recruiting NCT03267316 - A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors Phase 1/Phase 2
Recruiting NCT04970056 - Pancreatic Cancer Early Detection Consortium
Terminated NCT04046887 - Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC) Phase 1
Recruiting NCT05964621 - Venous Thromboembolism in Primary Pancreatic Tumour Resection
Active, not recruiting NCT04827953 - Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT04291651 - UCSF PANC Cyst Registry
Recruiting NCT05977322 - A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. Phase 1
Recruiting NCT05692596 - The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Active, not recruiting NCT04853017 - A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors Phase 1
Active, not recruiting NCT04862260 - Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma Early Phase 1
Completed NCT03770117 - Study of the Effect of Prehabilitation on Markers of Sarcopenia in Patients Undergoing Pancreatoduodenectomy for Malignant Disease
Completed NCT02259114 - A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) Phase 1
Recruiting NCT04146298 - Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer Phase 1/Phase 2